Company intelligence / Profile preview

Hexmed

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Suzhou Hexmed Biotech is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company leverages its structure-based drug design (SBDD) platform to target high-value biological pathways in oncology, metabolic diseases, and immunology. Its lead program, HMD3011, is a potent URAT1 inhibitor currently in clinical development for the treatment of hyperuricemia and gout. Hexmed's pipeline also includes HMD3002, a hematopoietic progenitor kinase 1 (HPK1) inhibitor in Phase 1 trials for solid tumors, and several preclinical candidates targeting TYK2 and SOS1.

Therapeutic areas: OncologyImmunologyRheumatologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Hexmed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hexmed.

Explore the full profile